摘要: |
【目的】探讨超声组学对乳腺BI-RADS 4类病变的良恶性鉴别诊断价值。【方法】前瞻性收集本院2018年6月至2019年12月期间乳腺超声发现的、有病理结果的BI-RADS 4类病变,共计223例。将研究人群按时间节点分为训练组(114例)和验证组(109例)。基于训练组病例建立乳腺病灶的超声组学评分指标。绘制超声组学评分的受试者工作特征(receiver operating characteristic,ROC)曲线,以曲线下面积(area under the curve,AUC)定量评估超声组学评分鉴别BI-RADS 4类病变良恶性的效能,计算其敏感性和特异性,并于验证组中验证其诊断效能。【结果】纳入的223个病例中,恶性占32.29%。训练组和验证组的恶性占比分别为28.95%、35.78%。超声组学评分在训练组和验证组的AUC及其95%置信区间分别为0.826(0.743-0.909)和0.810(0.723-0.898)。在训练组中,超声组学评分鉴别BI-RADS 4类病变良恶性的敏感性和特异性分别为78.79%和81.48%。在验证组中,其对应的敏感性和特异性分别为66.67%和82.86%。【结论】超声组学评分指标对乳腺BI-RADS 4类病变具备良好的鉴别诊断价值。 |
关键词: 超声组学,乳腺,BI-RADS,鉴别诊断 |
DOI: |
投稿时间:2020-02-17修订日期:2020-04-16 |
基金项目:基金项目:中山市社会公益科技研究项目(2019B1083) |
|
Differential Diagnosis Value of Ultrasomics in Breast Lesions of BI-RADS Category 4 |
LUO Weiquan,HUANG Xiaowen,ZENG Fuqiang,CHEN Xiang |
() |
Abstract: |
【Purpose】To explore the value of ultrasomics in differential diagnosis of benign and malignant breast lesions of BI-RADS category 4.【Methods】A total of 223 patients with BI-RADS category 4 breast lesions with pathology results were reviewed prospectively from June 2018 to December 2019. The study population was divided into the training group (n=114) and validation group (n=109). The ultrasomics score of breast lesion was developped based on the training group. Receiver operating characteristic (ROC) curve of the ultrasomics score was plotted. Area under the curve (AUC) was calculated to quantitatively assess the differential diagnostic performance of ultrasomics score. The sensitivity and specificity were calculated and verified in the validation group.【Results】Among the 223 lesions included, malignancy accounted for 32.29%. The malignant proportions in the training and validation groups were 28.95% and 35.78%, respectively. The AUC with 95% confidence interval of the ultrasomics score in the training and validation groups were 0.826 (0.743-0.909) and 0.810 (0.723-0.898), respectively. In the training group, the sensitivity and specificity of ultrasomics scores to distinguish benign and malignant BI-RADS category 4 lesions were 78.79% and 81.48%, respectively. In the validation group, the corresponding sensitivity and specificity were 66.67% and 82.86%, respectively.【Conclusion】The ultrasomics score has good differential diagnosis value in breast lesions of BI-RADS category 4. |
Key words: Ultrasomics Breast BI-RADS Differential diagnosis |